MINNEAPOLIS, MN- The University of Minnesota has become the third location in the United States to open a promising cell-based cancer immunotherapy clinical trial for the treatment of advanced solid tumors. The multicentered trial is investigating the safety and activity of a universal, off-the-shelf natural killer (NK) cell product, building off of the groundbreaking NK research done by Jeffrey Miller, MD, Deputy Director of the Masonic Cancer Center and Professor of Medicine at the University of Minnesota Medical School.
Designer molecule will activate the patient's own immune cells to attack cancer
MINNEAPOLIS, MN- September 19, 2019 -The discovery of tri-specific natural killer engagers (TriKE™), a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially, has led to a new Phase I, first-in-human study to treat leukemia. The study is opening exclusively at the University of Minnesota Medical Center, and is being sponsored by GT Biopharma, Inc.
The Masonic Cancer Center, University of Minnesota is hosting the first-ever Cancer Center Community Impact Forum (CCCIF)
Peter Villalta, PhD, has been appointed as the Director of the Analytical Biochemistry Shared Resource at the Masonic Cancer Center. After spending over 20 years as the coordinator of the mass spectrometry facility (part of the Analytical Biochemistry Shared Resource) under the leadership and guidance of Drs. Stephen Hecht and Robert Turesky, Villalta will take over leadership of this centralized resource on September 1, 2019. Dr. Turesky is stepping down as the current Director to focus on his research.
The Masonic Cancer Center team is saddened by the loss of Judy Erdahl, a longtime friend, and an advocate of the cancer center.
Judy passed away this morning surrounded by loved ones after a lengthy battle with metastatic breast cancer. She is survived by her husband Steve, and their two adult sons, Luke and Ranen.
Emil Lou, MD, PhD, FACP, Assistant Professor of Medicine, Division of Hematology, Oncology, and Transplantation (HOT), has been appointed Medical Director of the Masonic Cancer Center Clinical Trials Office (CTO). This new role will begin on September 1, 2019.
MINNEAPOLIS - A team led by Reuben Harris, PhD, Professor in the Department of Biochemistry, Molecular Biology, and Biophysics (BMBB), and Douglas Yee, MD, Director of the Masonic Cancer Center, and Professor in the Department of Medicine and Pharmacology, were recently awarded a multi-million dollar program project grant P01 from the National Cancer Institute (NCI).